USP to Open BioPharma Analytical Innovation Summit with Plenary on Monoclonal Antibody Standards
核心洞察
The United States Pharmacopeia (搜索) will open the BioPharma Analytical Innovation Summit 2026 with a plenary on its emerging standards framework for monoclonal antibody characterization.
USP's emerging standards address gaps in charge variant and bioactivity analysis, where stakeholders identified a need for more product-specific guidance.
USP published its first product-specific emerging standards for biologics on June 1, 2026, covering epoetin, interferon beta-1a, rituximab, and bevacizumab.
The United States Pharmacopeia (搜索) (USP) will present at the BioPharma Analytical Innovation Summit 2026, a one-day technical summit taking place September 16 at The Desmond Hotel in Malvern, Pennsylvania. The free summit, powered by Agilent Technologies (搜索), brings together analytical development, QC, and late-stage R&D and formulation scientists from across Greater Philadelphia and the Mid-Atlantic.
The day opens at 9:00 a.m. with a plenary from Dr. Kishan Chandra of USP, titled "Enhancing Analytical Confidence in mAbs: USP's Integrated Approach with Emerging Standards and Reference Standards." Attendees will have access to USP scientists at three points across the day, including Dr. Julie Zhang, who is set to lead the Protein & Antibody Therapeutics track, and Dr. Edmond Biba, Principal Scientist in USP's General Chapters – Science Division, who co-presents a session on orthogonal technologies for biomolecule characterization with Agilent's Derek Lohmann.
Closing the Gap in mAb Characterization
According to the abstract provided, monoclonal antibodies require robust analytical characterization to support quality, safety, and comparability. However, there is no common global expectation for which analytical methods are appropriate, or for what analytical performance should look like. The abstract states that this gap creates inefficiency and inconsistency in two places: in product testing itself, and in the interpretation of the resulting data.
USP's existing tools address part of the problem. General chapters, reference standards, and analytical reference materials cover two categories of risk: across biologics, microbial contamination and particulates; and specific to mAbs as a product class, aggregation and glycosylation.
According to the abstract, stakeholders identified two attributes where more product-specific guidance is needed: charge variants and bioactivity. Emerging standards are USP's response to that gap.
How USP Defines Emerging Standards
The abstract is specific about scope. Emerging standards are early-development concepts — not official compendial standards, and not proposed ones. They may be considered for compendial development in future. They provide public, science-based analytical methods and system suitability criteria, with the purpose of supporting assessment and monitoring of method performance while preserving flexibility in analytical approach. Product-specific specifications remain with the appropriate regulatory authorities.
Reference standards support the framework in practice as well-characterized materials used in method development, system suitability testing, validation, comparability studies, and performance monitoring. The stated goal is improved method robustness, reduced uncertainty, easier regulatory alignment, and more consistent evaluation of monoclonal antibodies.
First Emerging Standards Published
USP published its first product-specific emerging standards for biologics on June 1, 2026, covering epoetin, interferon beta-1a, rituximab, and bevacizumab, with accompanying physical reference standards. They were released through USP's Emerging Standards Platform and opened for public comment. USP has signaled the emerging standards portfolio will expand toward additional high-impact therapeutic proteins and monoclonal antibodies, making the current set a template rather than an endpoint.
Regional Significance
The corridor from Malvern and King of Prussia through Philadelphia into South Jersey and Delaware carries a dense concentration of QC and analytical development groups, along with a growing number of CDMOs running other organizations' methods against other organizations' expectations. For those teams, method ambiguity carries a cost: disputed results drive repeat investigations, repeat transfers, and delayed release.
The expertise that resolves those disputes tends to sit on the bench rather than in submissions. A one-day regional summit puts that experience in the same room as the people building the framework.
Also on the Agenda
Agilent application scientists will be on site alongside running instrumentation, including two systems new this year: the 6230C TOF, launched at ASMS, and the 1260 Infinity III FLD, a new detector module with a new flow cell added to the Infinity III series. A 10:00 a.m. innovation session covers HRMS-powered multi-attribute method workflows. Agilent states that its MAM solution for OpenLab CDS is aligned with USP General Chapter <1060>, "Mass Spectrometry-Based Multi-Attribute Method for Therapeutic Proteins," which became official August 1, 2025. The three midday tracks cover Peptide Therapeutics, Oligonucleotide & mRNA Therapeutics, and Protein & Antibody Therapeutics.